GlassScriptPhysician profile
Damian Silbermins
NPI 1922207117
$276,896.75
in general payments reported to CMS, 2019-2025
83 companies · $61K in 2025
The $61K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $20K · 2021: $59K · 2022: $6,533 · 2023: $8,276 · 2024: $34K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Consulting Fee: $27K · Food and Beverage: $10K · Travel and Lodging: $2,340 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $4.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,268.00 |
| Consulting Fee | $26,702.50 |
| Food and Beverage | $10,452.33 |
| Travel and Lodging | $2,340.38 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $4.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $179,798.35 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Celgene Corporation | $27,349.82 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $13,144.73 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Jazz Pharmaceuticals INC. | $9,757.96 | 2020-2025 | Zepzelca |
| Novartis Pharmaceuticals Corporation | $7,990.25 | 2019-2025 | |
| Janssen Biotech, INC. | $7,462.32 | 2019-2025 | Tecvayli, Erleada, Darzalex |
| Incyte Corporation | $6,467.46 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Agios Pharmaceuticals, INC. | $4,361.48 | 2019-2020 | |
| Seagen INC. | $2,718.38 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Beone Medicines USA, INC. | $2,058.25 | 2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $1,989.93 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Rigel Pharmaceuticals, INC. | $1,365.57 | 2019-2023 | Tavalisse, Rezlidhia |
| Bayer Healthcare Pharmaceuticals INC. | $1,058.87 | 2019-2025 | |
| Pfizer INC. | $822.03 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $803.94 | 2019-2025 | Keytruda, Lynparza, Welireg |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $775.57 | 2019-2025 | Venclexta, Tecentriq, Polivy |
| Astellas Pharma US INC | $713.45 | 2019-2025 | Vyloy, Xtandi, Padcev |
| Beigene, LTD. | $525.00 | 2021 | |
| Exelixis INC. | $501.55 | 2022-2024 | Cabometyx |
| Amgen INC. | $500.66 | 2019-2023 | Lumakras |
| Ipsen Biopharmaceuticals, INC | $467.47 | 2019-2024 | Onivyde, Somatuline Depot, Tazverik |
| Abbvie INC. | $466.77 | 2019-2025 | Venclexta |
| Beigene USA, INC. | $380.18 | 2020-2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $351.81 | 2019-2023 | Imbruvica, Epkinly |
| Glaxosmithkline, LLC. | $334.44 | 2020-2025 | Ojjaara, Zejula, Shingrix |
| Janssen Pharmaceuticals, INC | $285.93 | 2019-2024 | Xarelto |
| Genzyme Corporation | $265.30 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $208.24 | 2020-2025 | Fruzaqla, Alunbrig |
| Emd Serono, INC. | $189.39 | 2019-2024 | Bavencio |
| Eisai INC. | $174.76 | 2019-2025 | |
| Tempus Ai, INC | $173.48 | 2024-2025 | Xt Cdx |
| Coherus Oncology, INC. | $165.43 | 2020-2024 | |
| Taiho Oncology, INC. | $155.21 | 2022-2025 | |
| Tersera Therapeutics LLC | $151.84 | 2022-2025 | Zoladex |
| Shield Therapeutics INC | $147.63 | 2024 | |
| G1 Therapeutics, INC. | $147.57 | 2022-2023 | Cosela |
| Histosonics, INC. | $141.87 | 2025 | |
| Lilly USA, LLC | $137.61 | 2019-2024 | Jardiance, Retevmo, Jaypirca |
| Novocure INC. | $133.63 | 2019-2025 | Optune, Optune Lua (Novottf-200t) |
| Morphosys, US INC. | $132.66 | 2021-2023 | Monjuvi |
| Array Biopharma INC | $132.46 | 2021-2024 | Lorbrena, Xalkori, Braftovi |
| Adc Therapeutics America, INC. | $131.11 | 2021-2025 | |
| Puma Biotechnology, INC. | $122.12 | 2019-2025 | |
| Blueprint Medicines Corporation | $113.37 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $103.26 | 2020-2023 | Givlaari |
| Kite Pharma, INC. | $101.55 | 2020-2023 | |
| Aveo Pharmaceuticals, INC. | $100.03 | 2021-2025 | Fotivda |
| Comsort, INC | $100.00 | 2019 | |
| Karyopharm Therapeutics INC. | $90.73 | 2020-2023 | Xpovio |
| Kyowa Kirin, INC. | $86.24 | 2019-2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.32 | 2019-2021 | |
| Foundation Medicine, INC. | $69.69 | 2019-2023 | |
| Gilead Sciences, INC. | $69.32 | 2019-2024 | |
| Geron Corporation | $59.69 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $59.11 | 2023-2024 | Krazati |
| Alexion Pharmaceuticals, INC. | $57.98 | 2025 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.78 | 2020-2024 | Relistor |
| Pharmacosmos Therapeutics INC. | $44.80 | 2024-2025 | Monoferric |
| Adaptive Biotechnologies Corporation | $43.42 | 2022-2023 | Clonoseq |
| Dova Pharmaceuticals | $42.23 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $39.82 | 2019-2020 | |
| Stemline Therapeutics INC. | $36.09 | 2025 | Orserdu |
| Clovis Oncology, INC. | $28.62 | 2019 | |
| Recordati_rare_diseases_inc. | $27.69 | 2024 | Panhematin |
| Lexicon Pharmaceuticals, INC. | $25.20 | 2019 | |
| Servier Pharmaceuticals LLC | $24.45 | 2024 | |
| Verastem, INC. | $24.08 | 2019 | |
| Tg Therapeutics, INC. | $20.65 | 2022 | |
| Syndax Pharmaceuticals, INC. | $19.60 | 2025 | |
| Portola Pharmaceuticals, LLC | $18.97 | 2020 | |
| Sobi, INC | $18.80 | 2022 | |
| Secura Bio, INC. | $18.69 | 2019 | |
| Deciphera Pharmaceuticals INC. | $18.59 | 2021 | |
| Cti Biopharma Corp. | $18.21 | 2023 | Vonjo |
| Regeneron Healthcare Solutions, INC. | $17.70 | 2019 | |
| Myovant Sciences INC. | $17.54 | 2021 | |
| Immunocore Limited | $17.40 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.21 | 2022 | |
| Medtronic USA, INC. | $14.59 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.94 | 2019 | |
| Vifor Pharma, INC. | $11.75 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damian Silbermins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.